1. 1048OM7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort. (23rd October 2018) Authors: Cho, B C; Daste, A; Ravaud, A; Salas, S; Isambert, N; McClay, E; Awada, A; Borel, C; Gulley, J; Ojalvo, L; Helwig, C; Rolfe, P A; Penel, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1832PDPhase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). (23rd October 2018) Authors: Hollebecque, A; de Bono, J; Plummer, R; Isambert, N; Martin-Romano, P; Baudin, E; Mora, S; Harding, A; Nguyen, A; Filvaroff, E; Lamba, M; Liu, K; De Alvaro, J; DiMartino, J; Zuraek, M; Nikolova, Z Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 28TiPCHECK'UP: A prospective cohort study to identify predictive factors of response and mechanisms of resistance to PD-1 and PD-L1 antagonists. (17th December 2018) Authors: Penault-Llorca, F; Caux, C; Depil, S; Le Tourneau, C; Pérol, M; Robert, C; Soumelis, V; Couch, D; Isambert, N; Fernandez, Y; Filleron, T; Vassal, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 643PM7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with post-platinum esophageal adenocarcinoma (EAC): Preliminary results from a phase I cohort. (23rd October 2018) Authors: Tan, B; Khattak, A; Felip, E; Kelly, K; Rich, P; Wang, D; Helwig, C; Dussault, I; Ojalvo, L; Isambert, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 7OPhase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). (27th February 2019) Authors: Hollebecque, A; de Bono, J S; Plummer, R; Isambert, N; Martin-Romano, P; Baudin, E; Mora, S; Filvaroff, E; Lamba, M; Nikolova, Z Journal: Annals of oncology Issue: Volume 30(2019)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 85PEvaluation of the safety and the tolerability of durvalumab plus tremelimumab combined with FOLFOX in metastatic colorectal cancer (MEDITREME). (17th December 2018) Authors: Fumet, J-D; Isambert, N; Hervieu, A; Zanetta, S; Guion, J-F; Hennequin, A; Rederstorff, E; Bertaut, A; Ghiringhelli, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗